Intervention effect discussion of recombinant human interferon beta-1b for injection in the treatment of relapsing remitting multiple sclerosis / 中国医师进修杂志

ABSTRACT

Objective To explore the clinical efficacy and safety of recombinant human interferon beta-1b for injection (rhINFβ-1b) in the treatment of relapsing remitting multiple sclerosis (RRMS). Methods Thirty patients with RRMS were selected. According to the condition of accepting rhINFβ-1b for treatment, they were divided into intensification treatment group (11 cases) and routine treatment group (19 cases). They were followed up for 24 months, all the patients′laboratory examination and imaging examination were performed. The scores of clinical extended disability scale (EDSS) and the number of recurrences were compared between the two groups before and after the treatment. In the initial admission (T0), at the end of treatment (T1), 6 months of follow-up (T2), 12 months of follow-up (T3) and 18 months of follow-up (T4), the sequence of MRI T2and the number of enhanced scan lesions were observed, and the adverse drug reactions and their severity were evaluated. The ROC curve of cystatin C level in cerebrospinal fluid(CSF) was drawn to comprehensively evaluate the efficacy of drug intervention. Results After treatment, the scores of EDSS in intensification treatment group were significantly decreased (P < 0.05). The scores of EDSS and the number of annual recurrence in intensification treatment group were significantly lower than those in conventional treatment group (1.59 ± 0.75) scores vs. (4.07 ± 0.95) scores, (0.93 ± 0.38) times/year vs. (2.41 ± 0.54) times/year, there were significant differences (P＜0.01). The number of lesions at T0-T4time point in T2sequence and enhanced scan focus in intensification treatment group decreased. However, in conventional treatment group the number of lesions in T2sequences at T0-T4time point showed an upward trend, and the number of lesions at enhanced scan showed a broken line fluctuation. The results ROC curve showed that the area under the curve of intensification treatment group was 0.947 and the area under the conventional treatment group was 0.899. Conclusions rhINFβ-1b can effectively improve symptoms, significantly reduce the clinical relapse and MRI active lesions in patients with RRMS, slow down the progression of the disease, and have fewer adverse reactions.